Rein Therapeutics (RNTX) Competitors $1.51 -0.03 (-1.95%) As of 07/3/2025 01:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesSEC FilingsTrendsBuy This Stock RNTX vs. FATE, CRBU, NKTX, PLX, VXRT, CRDL, IKT, FTLF, UPXI, and GLSIShould you be buying Rein Therapeutics stock or one of its competitors? The main competitors of Rein Therapeutics include Fate Therapeutics (FATE), Caribou Biosciences (CRBU), Nkarta (NKTX), Protalix BioTherapeutics (PLX), Vaxart (VXRT), Cardiol Therapeutics (CRDL), Inhibikase Therapeutics (IKT), FitLife Brands (FTLF), Upexi (UPXI), and Greenwich LifeSciences (GLSI). These companies are all part of the "pharmaceutical products" industry. Rein Therapeutics vs. Its Competitors Fate Therapeutics Caribou Biosciences Nkarta Protalix BioTherapeutics Vaxart Cardiol Therapeutics Inhibikase Therapeutics FitLife Brands Upexi Greenwich LifeSciences Rein Therapeutics (NASDAQ:RNTX) and Fate Therapeutics (NASDAQ:FATE) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, media sentiment, profitability, dividends, analyst recommendations and valuation. Is RNTX or FATE more profitable? Rein Therapeutics has a net margin of 0.00% compared to Fate Therapeutics' net margin of -1,318.93%. Fate Therapeutics' return on equity of -47.17% beat Rein Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Rein TherapeuticsN/A -86.07% -31.11% Fate Therapeutics -1,318.93%-47.17%-34.60% Which has preferable earnings and valuation, RNTX or FATE? Rein Therapeutics has higher earnings, but lower revenue than Fate Therapeutics. Fate Therapeutics is trading at a lower price-to-earnings ratio than Rein Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRein TherapeuticsN/AN/A-$62.88M-$2.86-0.53Fate Therapeutics$13.63M9.63-$186.26M-$1.49-0.77 Does the media refer more to RNTX or FATE? In the previous week, Fate Therapeutics had 5 more articles in the media than Rein Therapeutics. MarketBeat recorded 5 mentions for Fate Therapeutics and 0 mentions for Rein Therapeutics. Fate Therapeutics' average media sentiment score of 0.43 beat Rein Therapeutics' score of 0.00 indicating that Fate Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Rein Therapeutics Neutral Fate Therapeutics Neutral Do insiders and institutionals have more ownership in RNTX or FATE? 90.9% of Rein Therapeutics shares are owned by institutional investors. Comparatively, 97.5% of Fate Therapeutics shares are owned by institutional investors. 5.1% of Rein Therapeutics shares are owned by insiders. Comparatively, 5.5% of Fate Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has more volatility and risk, RNTX or FATE? Rein Therapeutics has a beta of 1.22, meaning that its stock price is 22% more volatile than the S&P 500. Comparatively, Fate Therapeutics has a beta of 2.18, meaning that its stock price is 118% more volatile than the S&P 500. Do analysts rate RNTX or FATE? Fate Therapeutics has a consensus target price of $3.83, suggesting a potential upside of 234.79%. Given Fate Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Fate Therapeutics is more favorable than Rein Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rein Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Fate Therapeutics 0 Sell rating(s) 7 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.13 SummaryFate Therapeutics beats Rein Therapeutics on 11 of the 15 factors compared between the two stocks. Get Rein Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RNTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RNTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RNTX vs. The Competition Export to ExcelMetricRein TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$33.45M$2.90B$5.53B$9.05BDividend YieldN/A2.44%5.24%4.02%P/E Ratio-0.5321.5627.5120.24Price / SalesN/A281.76416.89118.64Price / Cash3.3742.7336.8958.07Price / Book3.517.518.035.67Net Income-$62.88M-$55.05M$3.18B$249.13M7 Day Performance2.72%4.61%2.90%3.28%1 Month Performance-22.56%4.72%3.71%5.56%1 Year PerformanceN/A5.92%36.03%21.13% Rein Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RNTXRein TherapeuticsN/A$1.51-1.9%N/AN/A$33.45MN/A-0.539Gap UpFATEFate Therapeutics4.1795 of 5 stars$1.04-5.5%$3.83+268.6%-63.8%$126.06M$13.63M-0.70550News CoverageAnalyst RevisionCRBUCaribou Biosciences2.309 of 5 stars$1.26-6.7%$8.50+574.6%-15.0%$125.56M$9.99M-0.78100News CoverageAnalyst UpgradeHigh Trading VolumeNKTXNkarta2.273 of 5 stars$1.66-4.0%$14.33+763.5%-67.2%$122.76MN/A-1.10140PLXProtalix BioTherapeutics2.9221 of 5 stars$1.54+6.2%$15.00+874.0%+48.6%$122.60M$59.76M-11.85200High Trading VolumeVXRTVaxart2.2875 of 5 stars$0.49-7.1%$3.00+506.7%-33.1%$121.57M$28.70M-1.83120CRDLCardiol Therapeutics2.0768 of 5 stars$1.41-4.1%$8.00+467.4%-21.0%$121.50MN/A-4.1520Positive NewsGap UpIKTInhibikase Therapeutics1.378 of 5 stars$1.62-1.8%$6.50+301.2%+64.3%$120.43M$260K-0.616News CoverageHigh Trading VolumeFTLFFitLife Brands4.0619 of 5 stars$12.81+0.2%$20.50+60.0%-7.3%$120.11M$64.47M15.2520High Trading VolumeUPXIUpexi3.1571 of 5 stars$2.60-17.7%$16.00+515.4%-60.0%$119.81M$26M0.00130Upcoming EarningsGap UpHigh Trading VolumeGLSIGreenwich LifeSciences1.5193 of 5 stars$8.99+0.7%$39.00+333.8%-39.9%$119.38MN/A-7.133 Related Companies and Tools Related Companies FATE Competitors CRBU Competitors NKTX Competitors PLX Competitors VXRT Competitors CRDL Competitors IKT Competitors FTLF Competitors UPXI Competitors GLSI Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RNTX) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rein Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rein Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RNTX Stock Alerts